10 Years of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC): A Systematic Review and Meta-Analysis.
Andrea Di GiorgioAntonio MacrìFederica FerracciManuela RobellaMario VisalocoGiovanni De ManzoniPaolo SammartinoAntonio SommarivaDaniele BiacchiFranco RovielloRoberta PastorinoDenise Pires MarafonStefano RotoloFrancesco CasellaMarco VairaPublished in: Cancers (2023)
PIPAC may be a useful treatment option for selected patients with PM, with acceptable grade 3 and 4 toxicity and promising survival benefit. Meta-analysis showed high heterogeneity of data among up-to-date available studies. In a subset analysis per primary tumor origin, pathological tumor regression was documented in 68% of the studies with acceptable heterogeneity. Pathological regression seems, therefore, a reliable outcome for PIPAC activity and a potential surrogate endpoint of treatment response. We recommend uniform selection criteria for patients entering a PIPAC program and highlight the urgent need to standardize items for PIPAC reports and datasets.
Keyphrases
- case control
- systematic review
- end stage renal disease
- single cell
- ejection fraction
- chronic kidney disease
- newly diagnosed
- peritoneal dialysis
- particulate matter
- air pollution
- prognostic factors
- heavy metals
- randomized controlled trial
- quality improvement
- electronic health record
- water soluble
- risk assessment
- radiation therapy
- artificial intelligence